IMDX (Insight Molecular Diagnostics) OCF Yield %: -13.70 (As of Jun. 25, 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $5.42
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics OCF Yield %?

Insight Molecular Diagnostics IMDX -0.19% 49 OCF Yield % is -13.70 as of Jun. 25, 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks worse than 79.07% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Insight Molecular Diagnostics's Trailing 12-Month Cash Flow from Operations is $-23.98 Mil, and Market Cap is $175.01 Mil. Therefore, Insight Molecular Diagnostics's OCF Yield % for today is -13.70%.

The historical rank and industry rank for Insight Molecular Diagnostics's OCF Yield % or its related term are showing as below:

IMDX' s OCF Yield % Range Over the Past 10 Years
Min: -170.18   Med: -30.08   Max: -5.68
Current: -13.7


During the past 13 years, the highest OCF Yield % of Insight Molecular Diagnostics was -5.68%. The lowest was -170.18%. And the median was -30.08%.

IMDX's OCF Yield % is ranked worse than
79.07% of 215 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.07 vs IMDX: -13.70

Insight Molecular Diagnostics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Insight Molecular Diagnostics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Insight Molecular Diagnostics OCF Yield % Related Terms


Insight Molecular Diagnostics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics OCF Yield % Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.96 -119.69 -112.94 -49.81 -10.31

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.69 -29.15 -18.95 -10.31 -28.85

IMDX vs BDSX, XGN, FONR: OCF Yield % Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics OCF Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's OCF Yield % falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Insight Molecular Diagnostics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-22.184 / 215.1225
=-10.31%

Insight Molecular Diagnostics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-7.639 * 4 / 105.89808
=-28.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -13.70 mean?
Insight Molecular Diagnostics (IMDX) has a OCF Yield % of -13.70 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #170 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 79.1%.
Is Insight Molecular Diagnostics' OCF Yield % too high?
Insight Molecular Diagnostics' current OCF Yield % is -13.70. Based on the distribution chart, Insight Molecular Diagnostics ranks #170 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' OCF Yield % compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #170 out of 215 companies for OCF Yield %. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median OCF Yield % is 1.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.07, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current OCF Yield % is -13.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.42 — trading 330.2% above its estimated fair value. The current OCF Yield % is -13.70. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current OCF Yield % is -13.70 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.42 is trading 330.2% above its estimated GF Value™ of $1.26. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • OCF Yield %: -13.70
  • GF Value™: $1.26 vs. price of $5.42 (330.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.42
Price
$1.26
GF Value